Steadman Philippon Research Institute

• Naoki Nakayama

  Principal investigator, program director

• Johnny Huard

  Chief scientific officer

Sources: reporter.nih.gov

• Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life

  Collaborator, Phase 1, Not yet recruiting, 50 people, 22 Jul 2026

• NCT06108063

  Phase 1/2, Recruiting, 120 people, 30 Oct 2023

• NCT05637216

  Collaborator, Phase 2, Active, not recruiting, 43 people, 5 Dec 2022

• NCT05025956

  Phase 1/2, Status unknown, 68 people, 30 Aug 2021

• NCT04815902

  Phase 1/2, Status unknown, 100 people, 25 Mar 2021

• NCT04212650

  Phase 1/2, Terminated, 1 person, 27 Dec 2019

• Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial

  Phase 1/2, Completed, 75 people, 26 Dec 2019

Sources: clinicaltrials.gov

• National Institute of Arthritis and Musculoskeletal and Skin Diseases

  R01, Articular Cartilage Tissue Engineering with Human Pluripotent Stem Cells, R01AR077045, US$309.9k, 2021–2027, 27 Mar 2025

• National Institute of Arthritis and Musculoskeletal and Skin Diseases

  UH3, The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis, UH3AR077748, US$551.6k, 2020–2025, 5 Aug 2024

• National Institute of Arthritis and Musculoskeletal and Skin Diseases

  R21, SMART stem cells that autonomously down-modulate TFG-β signaling for Articular Cartilage Repair, R21AR079075, US$155.1k, 2022–2024, 30 Jan 2023

Sources: reporter.nih.gov